Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Distinguishing primary from secondary membranous nephropathy
Monitoring patients with membranous nephropathy, over time, for trends in anti-PLA2R antibody levels
Anti-phospholipase A2 Receptor (PLA2R) antibodies are highly specific for the diagnosis of primary membranous nephropathy.
As many as 70% to 75% of patients with primary membranous nephropathy are positive for anti-PLA2R.
A titer increase, decrease, or disappearance generally precedes a change in clinical status.
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
PA2RI | Phospholipase A2 Receptor IFA, S | Yes | No |
ELISA (PA2RE) testing is always performed initially. IFA testing (PA2RI) is performed based on the ELISA results. If ELISA results are greater than or equal 2 or less than or equal to 20 the IFA testing will reflex on.
Enzyme-Linked Immunosorbent Assay (ELISA)